{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:34Z","timestamp":1793228374914,"version":"4.5.0"},"reference-count":229,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["23KJB350003"],"award-info":[{"award-number":["23KJB350003"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32301178"],"award-info":[{"award-number":["32301178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221045"],"award-info":[{"award-number":["BK20221045"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.pharmthera.2023.108527","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T09:00:13Z","timestamp":1694509213000},"page":"108527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies"],"prefix":"10.1016","volume":"250","author":[{"given":"Qiyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Mostafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108527_bb0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.addr.2019.02.008","article-title":"Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential","volume":"148","author":"Agrahari","year":"2019","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1087","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bmt.2016.45","article-title":"Decreased morbidity and mortality of autologous hematopoietic transplants for children with malignant central nervous system tumors: the \u201cHead Start\u201d trials, 1991-2009","volume":"51","author":"Altshuler","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0010","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41467-017-00952-3","article-title":"Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain","volume":"8","author":"Anraku","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11864-021-00874-9","article-title":"Immunosuppression in Medulloblastoma: Insights into Cancer immunity and immunotherapy","volume":"22","author":"Audi","year":"2021","journal-title":"Current Treatment Options in Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0020","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.24874","article-title":"Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A Children\u2019s oncology group study","volume":"61","author":"Bagatell","year":"2014","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0025","doi-asserted-by":"crossref","first-page":"15770","DOI":"10.1038\/ncomms15770","article-title":"MYC activation cooperates with Vhl and Ink4a\/Arf loss to induce clear cell renal cell carcinoma","volume":"8","author":"Bailey","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0030","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1172\/JCI57147","article-title":"Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target","volume":"121","author":"Baryawno","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154111","article-title":"Fenretinide (4-HPR) targets Caspase-9, ERK 1\/2 and the Wnt3a\/beta-catenin pathway in Medulloblastoma cells and Medulloblastoma cell spheroids","volume":"11","author":"Bassani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26409","article-title":"A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors","volume":"64","author":"Becher","year":"2017","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s41598-017-18100-8","article-title":"HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma","volume":"8","author":"Bell","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0050","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/hum.2020.101","article-title":"Design and rationale for first-in-human phase 1 Immunovirotherapy clinical trial of oncolytic HSV G207 to treat malignant pediatric cerebellar brain tumors","volume":"31","author":"Bernstock","year":"2020","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41417-019-0091-0","article-title":"Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice","volume":"27","author":"Bernstock","year":"2020","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0060","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jcyt.2019.06.009","article-title":"Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy","volume":"21","author":"Blaeschke","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbiotec.2009.08.019","article-title":"AGT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys","volume":"144","author":"Boado","year":"2009","journal-title":"Journal of Biotechnology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1462430","article-title":"Subgroup-specific immune and stromal microenvironment in medulloblastoma","volume":"7","author":"Bockmayr","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0075","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/s41388-018-0135-1","article-title":"Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma","volume":"37","author":"Bolin","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1088","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","article-title":"Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies","volume":"17","author":"Bowman","year":"2016","journal-title":"Cell.Rep."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0080","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100296","article-title":"Medulloblastoma-associated mutations in the DEAD-box RNA helicase DDX3X\/DED1 cause specific defects in translation","volume":"296","author":"Brown","year":"2021","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-84082-3","article-title":"Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells","volume":"11","author":"Buzzetti","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.actbio.2022.12.022","article-title":"Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy","volume":"157","author":"Cao","year":"2023","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0100","doi-asserted-by":"crossref","first-page":"312ra176","DOI":"10.1126\/scitranslmed.aab1803","article-title":"Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma","volume":"7","author":"Carter","year":"2015","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0105","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-16-2051","article-title":"FDA approval summary: Sonidegib for locally advanced basal cell carcinoma","volume":"23","author":"Casey","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0110","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1002\/eji.200737546","article-title":"Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity","volume":"37","author":"Castriconi","year":"2007","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2016.12.017","article-title":"Albumin nanoparticles for glutathione-responsive release of cisplatin: New opportunities for medulloblastoma","volume":"517","author":"Catanzaro","year":"2017","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within Medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1479","article-title":"Nanotherapeutic systems for local treatment of brain tumors","volume":"10","author":"Chakroun","year":"2018","journal-title":"Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121599","article-title":"Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer","volume":"287","author":"Chen","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0135","doi-asserted-by":"crossref","first-page":"41889","DOI":"10.1021\/acsami.9b14046","article-title":"Blood-brain barrier- and blood-brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/10611860902795399","article-title":"Synthesis, in vitro and in vivo characterization of glycosyl derivatives of ibuprofen as novel prodrugs for brain drug delivery","volume":"17","author":"Chen","year":"2009","journal-title":"Journal of Drug Targeting"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jconrel.2021.03.029","article-title":"BBB-crossing adeno-associated virus vector: An excellent gene delivery tool for CNS disease treatment","volume":"333","author":"Chen","year":"2021","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mattod.2022.04.001","article-title":"Iron oxide nanoparticle-mediated radiation delivery for glioblastoma treatment","volume":"56","author":"Chiarelli","year":"2022","journal-title":"Materials Today"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0155","article-title":"Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies","volume":"23","author":"Choi","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-011-0645-y","article-title":"Norcantharidin impairs medulloblastoma growth by inhibition of Wnt\/beta-catenin signaling","volume":"106","author":"Cimmino","year":"2012","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0165","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.04265","article-title":"Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis","volume":"6","author":"Cinatl","year":"2004","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00401-021-02358-4","article-title":"Subgroup and subtype-specific outcomes in adult medulloblastoma","volume":"142","author":"Coltin","year":"2021","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0175","doi-asserted-by":"crossref","first-page":"44079","DOI":"10.1038\/srep44079","article-title":"Selective targeting of HDAC1\/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma","volume":"7","author":"Coni","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0180","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00280-009-1127-1","article-title":"Medulloblastoma in childhood: Revisiting intrathecal therapy in infants and children","volume":"65","author":"Conroy","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0185","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1158\/1078-0432.CCR-16-2943","article-title":"Inhibition of CDK4\/6 by Palbociclib significantly extends survival in Medulloblastoma patient-derived xenograft mouse models","volume":"23","author":"Cook Sangar","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0195","doi-asserted-by":"crossref","first-page":"8562805","DOI":"10.1155\/2016\/8562805","article-title":"Neuroinvasion and inflammation in viral central nervous system infections","volume":"2016","author":"Dahm","year":"2016","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0200","doi-asserted-by":"crossref","first-page":"2206876","DOI":"10.1002\/adfm.202206876","article-title":"Non-invasive transdermal delivery systems with deep tissue penetrating ability for local ROS-modulating chemotherapy","volume":"32","author":"Deng","year":"2022","journal-title":"Advanced Functional Materials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1535-7163.MCT-14-0481","article-title":"Histone deacetylase 6 represents a novel drug target in the oncogenic hedgehog signaling pathway","volume":"14","author":"Dhanyamraju","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0215","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0037-1608657","article-title":"Neuroimaging of brain tumors: Pseudoprogression, Pseudoresponse, and delayed effects of chemotherapy and radiation","volume":"37","author":"Dietrich","year":"2017","journal-title":"Seminars in Neurology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0220","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0225","doi-asserted-by":"crossref","first-page":"20829","DOI":"10.18632\/oncotarget.4096","article-title":"A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies","volume":"6","author":"Drusco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0230","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/ijc.23948","article-title":"MicroRNA profiling in human medulloblastoma","volume":"124","author":"Ferretti","year":"2009","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0235","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/bjc.2013.764","article-title":"Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma","volume":"110","author":"Fiaschetti","year":"2014","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0240","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1535-7163.MCT-15-0371","article-title":"MK-4101, a potent inhibitor of the hedgehog pathway, is highly active against Medulloblastoma and basal cell carcinoma","volume":"15","author":"Filocamo","year":"2016","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0245","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1523\/JNEUROSCI.5203-05.2006","article-title":"Development of the deep cerebellar nuclei: Transcription factors and cell migration from the rhombic lip","volume":"26","author":"Fink","year":"2006","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0250","doi-asserted-by":"crossref","first-page":"52900","DOI":"10.18632\/oncotarget.9284","article-title":"IDO1 involvement in mTOR pathway: A molecular mechanism of resistance to mTOR targeting in medulloblastoma","volume":"7","author":"Folgiero","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004450","article-title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","volume":"10","author":"Foster","year":"2022","journal-title":"J.Immunother.Cancer."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0255","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1086","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0260","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/1078-0432.CCR-13-1425","article-title":"Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study","volume":"19","author":"Gajjar","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0265","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1158\/1078-0432.CCR-20-4226","article-title":"Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance","volume":"27","author":"Galbo","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.tig.2020.11.001","article-title":"Deconstructing sonic hedgehog medulloblastoma: Molecular subtypes, drivers, and beyond","volume":"37","author":"Garcia-Lopez","year":"2021","journal-title":"Trends in Genetics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0275","first-page":"1527","article-title":"Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy","volume":"61","author":"Geoerger","year":"2001","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0280","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10616-018-0260-2","article-title":"Molecular characterization of Wnt pathway and function of beta-catenin overexpression in medulloblastoma cell lines","volume":"70","author":"Geron","year":"2018","journal-title":"Cytotechnology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0290","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): An open label phase 1-2 trial","volume":"13","author":"Giugliani","year":"2018","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0295","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00401-012-0961-0","article-title":"Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem","volume":"123","author":"Grammel","year":"2012","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1097","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235852","article-title":"Astrocytes influence medulloblastoma phenotypes and CD133 surface expression","volume":"15","author":"Gronseth","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0300","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7390","article-title":"Single-cell analysis reveals effective siRNA delivery in brain tumors with microbubble-enhanced ultrasound and cationic nanoparticles","volume":"7","author":"Guo","year":"2021","journal-title":"Science Advances"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/gt.2012.12","article-title":"Neural stem cell-mediated CE\/CPT-11 enzyme\/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma","volume":"20","author":"Gutova","year":"2013","journal-title":"Gene Therapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0310","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1021\/jm8015409","article-title":"Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats","volume":"52","author":"Gynther","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1082","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11060-020-03591-9","article-title":"Medulloblastoma epigenetics and the path to clinical innovation","volume":"150","author":"Haltom","year":"2020","journal-title":"J.Neurooncol."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0315","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41577-022-00719-y","article-title":"Tumour immunotherapy: Lessons from predator-prey theory","volume":"22","author":"Hamilton","year":"2022","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2018.12.012","article-title":"Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma","volume":"445","author":"Han","year":"2019","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11060-018-2917-2","article-title":"Rethinking medulloblastoma from a targeted therapeutics perspective","volume":"139","author":"Hashimoto","year":"2018","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0330","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/s41586-022-05215-w","article-title":"Failure of human rhombic lip differentiation underlies medulloblastoma formation","volume":"609","author":"Hendrikse","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0335","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-Bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0340","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2017.08.024","article-title":"Oncogenic role of cytomegalovirus in medulloblastoma?","volume":"408","author":"Hortal","year":"2017","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0345","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.22935","article-title":"Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program","volume":"58","author":"Houghton","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0350","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/cas.12925","article-title":"Medulloblastoma stem cells: Promising targets in medulloblastoma therapy","volume":"107","author":"Huang","year":"2016","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0355","doi-asserted-by":"crossref","first-page":"8422","DOI":"10.1073\/pnas.0911838107","article-title":"Transventricular delivery of sonic hedgehog is essential to cerebellar ventricular zone development","volume":"107","author":"Huang","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1094","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/S0959-8049(01)00225-8","article-title":"Angiogenic profile of childhood primitive neuroectodermal brain tumours\/medulloblastomas","volume":"37","author":"Huber","year":"2001","journal-title":"Eur.J.Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41581-022-00648-y","article-title":"Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases","volume":"19","author":"Huynh","year":"2023","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0365","article-title":"Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity","volume":"32","author":"Hwang","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0370","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.tips.2015.05.006","article-title":"Targeting GLI factors to inhibit the hedgehog pathway","volume":"36","author":"Infante","year":"2015","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0375","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.canlet.2020.11.028","article-title":"Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of hedgehog-dependent medulloblastoma","volume":"499","author":"Infante","year":"2021","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0380","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/sj.onc.1210767","article-title":"Sonic hedgehog regulates Hes1 through a novel mechanism that is independent of canonical notch pathway signalling","volume":"27","author":"Ingram","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0385","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115354","article-title":"Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors","volume":"28","author":"Ji","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0395","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2021.07.042","article-title":"Cavitation-modulated inflammatory response following focused ultrasound blood-brain barrier opening","volume":"337","author":"Ji","year":"2021","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0400","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1165\/rcmb.2013-0127OC","article-title":"miR-326 is downstream of sonic hedgehog signaling and regulates the expression of Gli2 and smoothened","volume":"51","author":"Jiang","year":"2014","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0405","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1166\/jbn.2016.2262","article-title":"First in vivo testing of compounds targeting group 3 Medulloblastomas using an implantable microdevice as a new paradigm for drug development","volume":"12","author":"Jonas","year":"2016","journal-title":"Journal of Biomedical Nanotechnology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/ITT.S198162","article-title":"Immunotherapy for Medulloblastoma: Current perspectives","volume":"9","author":"Kabir","year":"2020","journal-title":"ImmunoTargets and Therapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35118-3","article-title":"Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma","volume":"13","author":"Kameda-Smith","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0420","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pbc.24989","article-title":"Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program","volume":"61","author":"Kang","year":"2014","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0425","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccr.2011.12.023","article-title":"A mouse model of the most aggressive subgroup of human medulloblastoma","volume":"21","author":"Kawauchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0430","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1074\/jbc.M109.066092","article-title":"Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects","volume":"285","author":"Kesavan","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0435","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fimmu.2019.00453","article-title":"Combining immune checkpoint inhibitors: Established and emerging targets and strategies to improve outcomes in melanoma","volume":"10","author":"Khair","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0440","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","article-title":"Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma","volume":"22","author":"Khatua","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0445","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.1073\/pnas.1911229117","article-title":"Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma","volume":"117","author":"Kim","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0450","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ped.14409","article-title":"Pediatric CNS imaging and long-term effects of irradiation in pediatric oncology patients","volume":"63","author":"Kluge","year":"2021","journal-title":"Pediatrics International"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0455","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00262-003-0408-5","article-title":"Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma","volume":"52","author":"Kobayashi","year":"2003","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0460","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41598-018-22902-9","article-title":"Self-assembling asymmetric peptide-dendrimer micelles - a platform for effective and versatile in vitro nucleic acid delivery","volume":"8","author":"Kokil","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0465","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/neuonc\/noy155","article-title":"DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas","volume":"21","author":"Korshunov","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0470","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2013.06.028","article-title":"Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems","volume":"171","author":"Kozlovskaya","year":"2013","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0475","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41598-017-01942-7","article-title":"Design, synthesis and biological evaluation of novel hedgehog inhibitors for treating pancreatic Cancer","volume":"7","author":"Kumar","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0480","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtn.2018.06.004","article-title":"Impact of miRNA-mRNA profiling and their correlation on Medulloblastoma tumorigenesis","volume":"12","author":"Kumar","year":"2018","journal-title":"Molecular Therapy--Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121138","article-title":"Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma","volume":"278","author":"Kumar","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121138","article-title":"Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma","volume":"278","author":"Kumar","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1091","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12885-018-4457-8","article-title":"M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0495","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41467-018-08269-5","article-title":"Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma","volume":"10","author":"Lee","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0500","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/0008-5472.CAN-14-0317","article-title":"Pyrvinium attenuates hedgehog signaling downstream of smoothened","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0505","doi-asserted-by":"crossref","first-page":"16662","DOI":"10.1039\/C6NR05055G","article-title":"Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells","volume":"8","author":"Li","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0510","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1039\/C4TB01828A","article-title":"PEG-b-AGE polymer coated magnetic nanoparticle probes with facile functionalization and anti-fouling properties for reducing non-specific uptake and improving biomarker targeting","volume":"3","author":"Li","year":"2015","journal-title":"Journal of Materials Chemistry B"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0515","doi-asserted-by":"crossref","first-page":"10523","DOI":"10.3390\/ijms221910523","article-title":"Tomato bushy stunt virus nanoparticles as a platform for drug delivery to Shh-dependent Medulloblastoma","volume":"22","author":"Lico","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0520","doi-asserted-by":"crossref","first-page":"eabh2290","DOI":"10.1126\/scisignal.abh2290","article-title":"DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway","volume":"15","author":"Liu","year":"2022","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0525","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/acssensors.2c00956","article-title":"Nonenzymatic multiamplified electrochemical detection of Medulloblastoma-relevant MicroRNAs from cerebrospinal fluid","volume":"7","author":"Liu","year":"2022","journal-title":"ACS Sensors"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0530","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1158\/0008-5472.CAN-07-1214","article-title":"Targeting human medulloblastoma: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin","volume":"67","author":"Lun","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0535","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/cancers13061220","article-title":"Liposome-imipramine blue inhibits sonic hedgehog Medulloblastoma in vivo","volume":"13","author":"MacDonald","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0540","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.30724","article-title":"Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues","volume":"123","author":"Majzner","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0545","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a Pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0550","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1038\/s41467-020-17953-4","article-title":"Wnt activation as a therapeutic strategy in medulloblastoma","volume":"11","author":"Manoranjan","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21232","article-title":"Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program","volume":"50","author":"Maris","year":"2008","journal-title":"Pediatr.Blood Cancer."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0555","doi-asserted-by":"crossref","first-page":"19177","DOI":"10.18632\/oncotarget.24951","article-title":"PD-L1 expression in medulloblastoma: An evaluation by subgroup","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1092","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41467-019-10458-9","article-title":"Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma","volume":"10","author":"Maximov","year":"2019","journal-title":"Nat.Commun."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0560","doi-asserted-by":"crossref","first-page":"11657","DOI":"10.1021\/acsami.1c00347","article-title":"Targeted regulation of blood-brain barrier for enhanced therapeutic efficiency of hypoxia-modifier nanoparticles and immune checkpoint blockade antibodies for glioblastoma","volume":"13","author":"Meng","year":"2021","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0565","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3181\/0612-RM-301","article-title":"Evaluation of poly (glycerol-adipate) nanoparticle uptake in an in vitro 3-D brain tumor co-culture model","volume":"232","author":"Meng","year":"2007","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0570","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2002574118","article-title":"An immunohistochemical study of lymphatic elements in the human brain","volume":"118","author":"Mezey","year":"2021","journal-title":"Proceedings. National Academy of Sciences. United States of America"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0575","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3477-0","article-title":"beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog\/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells","volume":"17","author":"Miele","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0580","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/1878-0261.12800","article-title":"Downregulation of miR-326 and its host gene beta-arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth","volume":"15","author":"Miele","year":"2021","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0585","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1158\/1078-0432.CCR-10-0395","article-title":"HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth","volume":"16","author":"Milde","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0590","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12948","article-title":"Extracellular vesicle-associated organotropic metastasis","volume":"54","author":"Mo","year":"2021","journal-title":"Cell Proliferation"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121395","article-title":"Comparison of three synthetic transferrin mimetic small peptides to promote the blood-brain barrier penetration of vincristine liposomes for improved glioma targeted therapy","volume":"613","author":"Mojarad-Jabali","year":"2022","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15430\/JCP.2019.24.2.79","article-title":"The roles of miRNAs in Medulloblastoma: A systematic review","volume":"24","author":"Mollashahi","year":"2019","journal-title":"Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0605","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3389\/fonc.2019.00824","article-title":"Role of GFI1 in epigenetic regulation of MDS and AML pathogenesis: Mechanisms and therapeutic implications","volume":"9","author":"Moroy","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0610","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1158\/0008-5472.CAN-13-0927","article-title":"Silencing of the miR-17\u223c92 cluster family inhibits medulloblastoma progression","volume":"73","author":"Murphy","year":"2013","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0615","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-022-02522-4","article-title":"Identification of low and very high-risk patients with non-WNT\/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts","volume":"145","author":"Mynarek","year":"2023","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0620","doi-asserted-by":"crossref","first-page":"30-z","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0625","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.stemcr.2018.04.014","article-title":"Epigenetic regulation by BAF complexes limits neural stem cell proliferation by suppressing Wnt signaling in late embryonic development","volume":"10","author":"Nguyen","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0630","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1158\/0008-5472.CAN-08-4710","article-title":"The miR-17\/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors","volume":"69","author":"Northcott","year":"2009","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0635","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature11327","article-title":"Subgroup-specific structural variation across 1,000 medulloblastoma genomes","volume":"488","author":"Northcott","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0640","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0645","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0650","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/emboj.2012.146","article-title":"Three decades of Wnts: A personal perspective on how a scientific field developed","volume":"31","author":"Nusse","year":"2012","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0655","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1248\/cpb.c20-00041","article-title":"Recent strategies for targeted brain drug delivery","volume":"68","author":"Ogawa","year":"2020","journal-title":"Chemical & Pharmaceutical Bulletin (Tokyo)"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0660","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-17-3140","article-title":"Adoptive immunotherapy using PRAME-specific T cells in Medulloblastoma","volume":"78","author":"Orlando","year":"2018","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0665","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bpa.12837","article-title":"Pathology, diagnostics, and classification of medulloblastoma","volume":"30","author":"Orr","year":"2020","journal-title":"Brain Pathology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0670","doi-asserted-by":"crossref","first-page":"20719","DOI":"10.1021\/acsami.7b02575","article-title":"One-step facile synthesis of highly magnetic and surface functionalized Iron oxide Nanorods for biomarker-targeted applications","volume":"9","author":"Orza","year":"2017","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0675","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/08982104.2019.1668011","article-title":"Formulation and evaluation of itraconazole liposomes for hedgehog pathway inhibition","volume":"30","author":"Pace","year":"2020","journal-title":"Journal of Liposome Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0680","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/ml1000307","article-title":"Discovery of NVP-LDE225, a potent and selective smoothened antagonist","volume":"1","author":"Pan","year":"2010","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0685","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3148-1","article-title":"In search of druggable targets for GBM amino acid metabolism","volume":"17","author":"Panosyan","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0690","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s12885-019-5742-x","article-title":"Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma","volume":"19","author":"Park","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0695","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/pbc.25313","article-title":"SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings","volume":"62","author":"Parkes","year":"2015","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0700","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41589-020-0563-4","article-title":"Dissecting the pol II transcription cycle and derailing cancer with CDK inhibitors","volume":"16","author":"Parua","year":"2020","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0705","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28983","article-title":"Drug penetration in pediatric brain tumors: Challenges and opportunities","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0710","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biomaterials.2019.03.029","article-title":"Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme","volume":"206","author":"Patil","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0715","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.devcel.2020.05.027","article-title":"DDX3X suppresses the susceptibility of hindbrain lineages to Medulloblastoma","volume":"54","author":"Patmore","year":"2020","journal-title":"Developmental Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0720","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccr.2011.12.021","article-title":"An animal model of MYC-driven medulloblastoma","volume":"21","author":"Pei","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0725","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven Medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0730","doi-asserted-by":"crossref","first-page":"56753","DOI":"10.1021\/acsami.0c17102","article-title":"In situ surface modification of microfluidic blood-brain-barriers for improved screening of small molecules and nanoparticles","volume":"12","author":"Peng","year":"2020","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0735","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203738119","article-title":"Miat and interacting protein Metadherin maintain a stem-like niche to promote medulloblastoma tumorigenesis and treatment resistance","volume":"119","author":"Peng","year":"2022","journal-title":"Proceedings. National Academy of Sciences. United States of America"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0740","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737140.2016.1184978","article-title":"The therapeutic potential of natural killer cells to target medulloblastoma","volume":"16","author":"Perez-Martinez","year":"2016","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0745","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.3389\/fimmu.2019.02294","article-title":"Microenvironmental heterogeneity in brain malignancies","volume":"10","author":"Perus","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1090","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1172\/JCI128644","article-title":"Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment","volume":"129","author":"Petty","year":"2019","journal-title":"J.Clin.Invest."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0750","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cmdc.201300217","article-title":"Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened","volume":"8","author":"Peukert","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0755","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1078-0432.CCR-15-0713","article-title":"Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine Medulloblastoma","volume":"22","author":"Pham","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0760","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma genotype dictates blood brain barrier phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0765","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12967-019-2055-4","article-title":"Medulloblastoma rendered susceptible to NK-cell attack by TGFbeta neutralization","volume":"17","author":"Powell","year":"2019","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0770","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","article-title":"GD2 CAR T cells against human glioblastoma","volume":"5","author":"Prapa","year":"2021","journal-title":"npj Precision Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0775","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194206","article-title":"Tis21-gene therapy inhibits medulloblastoma growth in a murine allograft model","volume":"13","author":"Presutti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0780","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1172\/JCI92710","article-title":"Hedgehog signaling drives medulloblastoma growth via CDK6","volume":"128","author":"Raleigh","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0785","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2008.12.016","article-title":"Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma","volume":"15","author":"Read","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0790","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/neuonc\/noab178","article-title":"Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse","volume":"24","author":"Richardson","year":"2022","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0795","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","article-title":"GDC-0449-a potent inhibitor of the hedgehog pathway","volume":"19","author":"Robarge","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0800","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature11213","article-title":"Novel mutations target distinct subgroups of medulloblastoma","volume":"488","author":"Robinson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0805","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup Medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0810","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trsl.2017.07.003","article-title":"Chimeric antigen receptor T-cell therapy for glioblastoma","volume":"187","author":"Rodriguez","year":"2017","journal-title":"Translational Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0815","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1007\/s13277-016-5119-6","article-title":"Laminin-adherent versus suspension-non-adherent cell culture conditions for the isolation of cancer stem cells in the DAOY medulloblastoma cell line","volume":"37","author":"de la Rosa","year":"2016","journal-title":"Tumour Biology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1081","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/neuonc\/noac061","article-title":"Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma","volume":"24","author":"Roesler","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0820","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12311-017-0899-9","article-title":"Epigenetic drivers in pediatric Medulloblastoma","volume":"17","author":"Roussel","year":"2018","journal-title":"Cerebellum"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0825","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bpa.12803","article-title":"Modeling pediatric medulloblastoma","volume":"30","author":"Roussel","year":"2020","journal-title":"Brain Pathology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0830","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa042176","article-title":"Treatment of early childhood medulloblastoma by postoperative chemotherapy alone","volume":"352","author":"Rutkowski","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0835","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1470-2045(17)30243-7","article-title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study","volume":"18","author":"Schwalbe","year":"2017","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0840","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.075","article-title":"Medulloblastoma arises from the persistence of a rare and transient Sox2(+) granule neuron precursor","volume":"31","author":"Selvadurai","year":"2020","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206394","article-title":"Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma","volume":"14","author":"Shackleford","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0855","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","article-title":"Second-generation molecular subgrouping of medulloblastoma: An international meta-analysis of group 3 and group 4 subtypes","volume":"138","author":"Sharma","year":"2019","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0860","article-title":"PI-3K inhibitors preferentially target CD15+ Cancer stem cell population in SHH driven Medulloblastoma","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0865","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.3390\/ijms21197195","article-title":"Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung Cancer: A review","volume":"21","author":"Slawinski","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0870","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2021.07.020","article-title":"Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation","volume":"520","author":"Song","year":"2021","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0875","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/cr.2016.50","article-title":"MYC - a thorn in the side of cancer immunity","volume":"26","author":"Spranger","year":"2016","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0880","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40259-018-0309-y","article-title":"Emerging Technologies for Delivery of biotherapeutics and gene therapy across the blood-brain barrier","volume":"32","author":"Stanimirovic","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0885","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.31041","article-title":"MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling","volume":"142","author":"Tang","year":"2018","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0890","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nm.3613","article-title":"Epigenetic targeting of hedgehog pathway transcriptional output through BET bromodomain inhibition","volume":"20","author":"Tang","year":"2014","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0895","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jnen\/nly045","article-title":"Poliovirus receptor (CD155) expression in pediatric brain tumors mediates Oncolysis of Medulloblastoma and pleomorphic Xanthoastrocytoma","volume":"77","author":"Thompson","year":"2018","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0900","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.29294","article-title":"MiR-34a deficiency accelerates medulloblastoma formation in vivo","volume":"136","author":"Thor","year":"2015","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0905","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/acs.jmedchem.9b00851","article-title":"Identification of novel medulloblastoma cell-targeting peptides for use in selective chemotherapy drug delivery","volume":"63","author":"Tjandra","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0910","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202000261","article-title":"Modulating the selectivity and stealth properties of ellipsoidal Polymersomes through a multivalent peptide ligand display","volume":"9","author":"Tjandra","year":"2020","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0915","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0920","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0809579106","article-title":"The miR-17\u223c92 cluster collaborates with the sonic hedgehog pathway in medulloblastoma","volume":"106","author":"Uziel","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0925","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.10.033","article-title":"Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies","volume":"314","author":"Varini","year":"2019","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0930","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2014-09-603357","article-title":"B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality","volume":"125","author":"Veenstra","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0935","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/0008-5472.CAN-06-3948","article-title":"Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci","volume":"67","author":"Veiseh","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0940","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1074\/jbc.M112.396762","article-title":"MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma","volume":"288","author":"Venkataraman","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1093","first-page":"232","article-title":"Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy","volume":"16","author":"Wang","year":"2022","journal-title":"Bioact.Mater."},{"key":"10.1016\/j.pharmthera.2023.108527_bb0945","doi-asserted-by":"crossref","first-page":"eaaw2672","DOI":"10.1126\/scitranslmed.aaw2672","article-title":"Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma","volume":"12","author":"Wang","year":"2020","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0950","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.expneurol.2012.11.014","article-title":"The role of stem cells and progenitors in the genesis of medulloblastoma","volume":"260","author":"Wang","year":"2014","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0955","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-neuro-070815-013838","article-title":"Medulloblastoma: From molecular subgroups to molecular targeted therapies","volume":"41","author":"Wang","year":"2018","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0960","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03201-6","article-title":"Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0965","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0970","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jconrel.2020.04.053","article-title":"ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice","volume":"323","author":"Wang","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0975","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/0008-5472.CAN-09-0342","article-title":"Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma","volume":"69","author":"Ward","year":"2009","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0980","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: A retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0985","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00401-012-0969-5","article-title":"Pleiotropic effects of miR-183\u223c96\u223c182 converge to regulate cell survival, proliferation and migration in medulloblastoma","volume":"123","author":"Weeraratne","year":"2012","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0990","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pharmaceutics13010015","article-title":"Focused ultrasound and microbubbles-mediated drug delivery to brain tumor","volume":"13","author":"Wu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108527_bb0995","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/med.21482","article-title":"Strategies to target the hedgehog signaling pathway for cancer therapy","volume":"38","author":"Xin","year":"2018","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1000","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101428","article-title":"Nanomedicine strategies to circumvent Intratumor extracellular matrix barriers for Cancer therapy","volume":"11","author":"Xu","year":"2022","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41418-021-00838-4","article-title":"Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2","volume":"29","author":"Xue","year":"2022","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1010","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/1541-7786.MCR-22-0182","article-title":"A Druggable UHRF1\/DNMT1\/GLI complex regulates sonic hedgehog-dependent tumor growth","volume":"20","author":"Yang","year":"2022","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1015","doi-asserted-by":"crossref","first-page":"43712","DOI":"10.18632\/oncotarget.6227","article-title":"miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jconrel.2021.12.034","article-title":"Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy","volume":"342","author":"Yang","year":"2022","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2008.07.003","article-title":"Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells","volume":"14","author":"Yang","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13659-015-0056-4","article-title":"Biflavone Ginkgetin, a novel Wnt inhibitor, suppresses the growth of Medulloblastoma","volume":"5","author":"Ye","year":"2015","journal-title":"Natural Products and Bioprospecting"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1035","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/0008-5472.CAN-21-4313","article-title":"PRC2 heterogeneity drives tumor growth in Medulloblastoma","volume":"82","author":"Yi","year":"2022","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10717544.2018.1431978","article-title":"Dual-targeting for brain-specific drug delivery: Synthesis and biological evaluation","volume":"25","author":"Yue","year":"2018","journal-title":"Drug Delivery"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1045","article-title":"Intranasal delivery of functionalized polymeric nanomaterials to the brain","volume":"11","author":"Zha","year":"2022","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41388-019-1036-7","article-title":"EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1\/p53 tumor suppressor pathway","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1055","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-020-00209-0","article-title":"Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human","volume":"17","author":"Zhang","year":"2020","journal-title":"Fluids and Barriers of the CNS"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1060","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cam4.2873","article-title":"Exosomal sonic hedgehog derived from cancer-associated fibroblasts promotes proliferation and migration of esophageal squamous cell carcinoma","volume":"9","author":"Zhao","year":"2020","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1065","article-title":"BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2014.05.072","article-title":"Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with \"lock-in\" function","volume":"82","author":"Zhao","year":"2014","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"Journal of Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2023.108527_bb1096","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.actbio.2017.09.009","article-title":"Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO(2)@LDH for anti-neuroblastoma therapy","volume":"63","author":"Zhu","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.pharmthera.2023.108527_bb1080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.03.025","article-title":"Highly efficacious and specific anti-glioma chemotherapy by tandem nanomicelles co-functionalized with brain tumor-targeting and cell-penetrating peptides","volume":"278","author":"Zhu","year":"2018","journal-title":"Journal of Controlled Release"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:37:39Z","timestamp":1759012659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":229,"alternative-id":["S0163725823001912"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108527","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108527"}}